Last Updated on January 17, 2021 by The Health Master
Dr Reddy’s Laboratories has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.
The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Earlier, the Data and Safety Monitoring Board (DSMB) reviewed the safety data from the phase 2 clinical trial of the vaccine and recommended phase 3 recruitment.
In its report, the DSMB concluded that no safety concerns were identified and the study met the primary endpoints of safety.
GV Prasad, Co-chairman and MD, Dr Reddy’s Laboratories said, “This is an important milestone in the progress of this pivotal clinical trial of the vaccine.
Also read | Phytopharmaceuticals: IPC invites suggestions from stakeholders
We expect to commence the phase 3 study within this month and will continue to fast-track our efforts to bring in a safe and efficacious vaccine for the Indian population”.
In September 2020, Dr Reddy’s partnered with Russian Direct Investment Fund (RDIF) to conduct the clinical trials of the Sputnik V vaccine and for its distribution rights in India.
Sputnik V developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against C-19 based on the established human adenoviral vector platform.
The vaccine’s efficacy is confirmed at 91.4 per cent based on data analysis of the final control point of clinical trials in Russia.
Currently, the vaccine’s clinical trials are underway in the UAE, Egypt, Venezuela and Belarus while it has been registered in Algeria, Argentina, Belarus, Bolivia and Serbia for inoculation.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
Follow and connect with us on Facebook and Linkedin
Go to main website, click here
Subscribe for daily free updates, click here
